China (Mainland)
Diamondsupplier 
factory supply 98% Rivaroxaban Form I powder CAS NO.366789-02-8
- FOB Price: USD: 1.00-999.00 /Kilogram Get Latest Price
- Min.Order: 1 Kilogram
- Payment Terms: L/C,D/A,D/P,T/T,Other
- Available Specifications:
Medicine Grade(1-99)KilogramMedicine Grade(100-1000)Kilogram
- Product Details
Keywords
- Rivaroxaban Form I
- 98% up
- factory supply
Quick Details
- ProName: factory supply 98% Rivaroxaban Form I ...
- CasNo: 366789-02-8
- Molecular Formula: C19H18ClN3O5S
- Appearance: White powder
- Application: Medicine Grade
- DeliveryTime: in 7 days afte your payment ( in stock...
- PackAge: 1kg/bag ;5kg/drum:25KG/drum
- Port: any port in China
- ProductionCapacity: 20 Metric Ton/Month
- Purity: 98% up
- Storage: in low tempreture
- Transportation: in low tempreture
- LimitNum: 1 Kilogram
Superiority
Why is SINOWAY:
1) Specialized in pharmaceutical and healthcare industrial for 34 years.
2) ISO 9001:2015 & SGS audited supplier .
3) Accept various payment terms : T.T 30-60 days.
4) We have warehouse in USA with quickly shipment .
5) We can do different terms of FOB ,CIF/CIP ,DDP ...
Why choose us
Our advantages of Rivaroxaban (CAS:366789-02-8) :
1. Quality: Form I,assay 98% up ,conform to USP/EP standard ,
2. Normal PSD D90＜100um & Micron PSD D90 ＜10um.
3. Documents: local GMP,WC and DMF. CEP is under applying. The price with documents is higher than without.
4. Large capacity & stock : 120~180kg per month with 800kg in stock for prompt shipment
5. Better payment terms : We can make use of Export Credit Insurance after confirming yr credit report accepted by Sinosure, accept Alibaba Trade Assurance
6. Various shipping ways for your choice : by air./ by sea / by courier (DHL/FedEx).
Details
Product Information
|
Product name |
Rivaroxaban |
|
CAS No. |
366789-02-8 |
|
Molecular Formula |
C19H18ClN3O5S |
|
Molecular Weight |
435.8813 |
|
Quality Standard |
98% up, Medicine Grade |
|
Appearance |
White powder |
COA of Rivaroxaban
|
TEST |
SPECIFICATION |
RESULTS |
|
Appearance |
White to off-white powder |
White powder |
|
Identification |
A: The infrared absorption of rivaroxaban corresponds to reference standards |
Conforms |
|
|
B: The retention time of the main peak of the sample solution corresponds to that of the system suitability solution, as obtained in the enantiomeric purity |
Conforms |
|
ENANTIOMERIC PURITY |
RVX RC01: NMT 0.15% |
None detected |
|
WATER (KF) |
NMT 0.5% |
0.2% |
|
SULPHATED ASH |
NMT 0.1% |
0.02% |
|
ACETIC ACID |
NMT 5000 ppm |
774 ppm |
|
RELATED SUBSTANCES(HPLC) |
RVX RC02: NMT 0.15% |
None detected |
|
RVX RC03: NMT 0.15% |
None detected |
|
|
RVX RC04: NMT 0.15% |
None detected |
|
|
RVX RC05: NMT 0.15% |
0.04 % |
|
|
RVX RC06: NMT 0.15% |
< disregard limit (0.03%) |
|
|
RVX RC07: NMT 0.15% |
None detected |
|
|
RVX RC08: NMT 0.15% |
None detected |
|
|
Any other individual impurity: NMT 0.10% |
0.07% |
|
|
Total impurities: NMT 0.5% |
0.15% |
|
|
RESIDUAL SOLVENTS (GC) |
Ethanol: NMT 5000 ppm |
26 ppm |
|
Toluene: NMT 890 ppm |
None detected |
|
|
Triethylamine: NMT 320 ppm |
None detected |
|
|
ASSAY |
NLT 98.0% & NMT 102.0% (on anhydrous basis) |
100.1% |
|
STORAGE |
Preserved in tight and light resistant container Temperature: ≤ 30。C |
|
|
CONCLUSION |
The product complies with the specification of In-house standard |
|
Usage
Function of Rivaroxaban
Rivaroxaban is an oral, bioavailable factor Xa inhibitor that selectively blocks the active site of factor Xa and does not require cofactors (such as antithrombin III) to exert its activity. Factor X is activated by endogenous and exogenous pathways as factor Xa (FXa), which plays an important role in the coagulation cascade.
1. Rivaroxaban is for adult patients with elective hip or knee replacement surgery to prevent venous thrombosis (VTE).
2. Rivaroxaban is used to treat adult venous thrombosis (DVT) and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT.
3. Rivaroxaban is for adult patients with non-valvular atrial fibrillation with one or more risk factors (for example: congestive heart failure, hypertension, age ≥75 years, history of diabetes, stroke or transient ischemic attack), to Reduce the risk of stroke and systemic embolism.
In the condition of well-controlled treatment with warfarin, there are limited data on the relative effectiveness of rivaroxaban in reducing the risk of stroke and systemic embolism compared with warfarin.
